help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khalfallah, Y.
Right arrow Articles by Sassolas, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khalfallah, Y.
Right arrow Articles by Sassolas, G.

Journal of Clinical Endocrinology & Metabolism, Vol 71, 354-359, Copyright © 1990 by Endocrine Society

ARTICLES

Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas

Y Khalfallah, B Claustrat, M Grochowicki, F Flocard, S Horlait, P Serusclat and G Sassolas
Centre de Medecine Nucleaire, Hopital Neurologique, Lyon, France.

The effects of a new PRL inhibitor, CV 205-502 (CV), on human macroprolactinomas were studied in nine patients according to a prospective protocol. Five patients had undergone surgery leaving tumor remnants and persistent hyperprolactinemia. The four others were de novo patients, two of whom had received short term treatment with Parlodel. Plasma PRL levels ranged from 235-6050 micrograms/L before treatment. The doses of CV used in this trial ranged from 0.075-0.600 mg. Plasma PRL normalized in eight of the nine patients during treatment with CV. The time to normalize varied from 2 weeks to 9 months, and the doses from 0.075-0.450 mg. A tumor volume reduction of more than 50% was obtained in all four patients who had not been operated on before CV treatment. Only one of the five patients with postoperative tumor remnants had no reduction in tumor size. The drug was generally well tolerated, and no patient interrupted the treatment. Slight and short-lasting gastrointestinal symptoms were noted in several patients, and a single episode of fainting occurred in one patient when the drug was not taken at bedtime as instructed. A noticeable and persistent weight loss with anorexia was noted in two patients. Since CV 205-502, administered in a single daily dose, has tolerable side-effects and is effective in reducing PRL secretion and tumor size, it can be considered to be a useful treatment for macroprolactinomas.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. Barlier and P. Jaquet
Quinagolide - a valuable treatment option for hyperprolactinaemia
Eur. J. Endocrinol., February 1, 2006; 154(2): 187 - 195.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, A. Di Sarno, M. L. Landi, S. Cirillo, F. Sarnacchiaro, G. Facciolli, R. Pivonello, M. Cataldi, B. Merola, L. Annunziato, et al.
Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage
J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3574 - 3579.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society